WallStSmart

Co-Diagnostics, Inc. Common Stock (CODX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 3518565% more annual revenue ($25.27B vs $718,170). SYK leads profitability with a 13.2% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 59/100 (C).

CODX

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 1/9Altman Z: -5.19

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CODX.

SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CODX4 strengths · Avg: 9.3/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
190.3%10/10

Revenue surging 190.3% year-over-year

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
30.8%8/10

Earnings expanding 30.8% YoY

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

CODX4 concerns · Avg: 2.8/10
Market CapQuality
$20.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-302.3%2/10

ROE of -302.3% — below average capital efficiency

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CODX

The strongest argument for CODX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 190.3% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : CODX

The primary concerns for CODX are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CODX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

CODX carries more volatility with a beta of 1.26 — expect wider price swings.

CODX is growing revenue faster at 190.3% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Co-Diagnostics, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?